Dupilumab Reduces COPD Hospitalizations, ED Visits, and Corticosteroid Use

Targeting Type 2 Inflammation in Chronic Obstructive Pulmonary Disease

Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity and mortality, driven largely by exacerbations that diminish quality of life and strain healthcare systems [1, 2]. While conventional therapies like bronchodilators are foundational, they can be insufficient for patients with specific inflammatory profiles [3, 2]. Research has identified a distinct subgroup of patients whose disease is characterized by type 2 inflammation, often indicated by a blood eosinophil count of 300 cells/µL or higher [4, 5]. This has prompted investigation into biologic therapies that target the underlying immune pathways, with the goal of reducing exacerbation frequency and improving outcomes in this T2-high population where standard care may not be adequate [6, 7, 8, 9]. A recent pooled analysis of two large clinical trials provides new data on how one such biologic, dupilumab, affects key clinical endpoints in this patient group.

Addressing the Burden of COPD Exacerbations

For patients with chronic obstructive pulmonary disease, acute exacerbations are the primary driver of morbidity, healthcare utilization, and mortality. These episodes of worsening respiratory symptoms often necessitate emergency department visits or hospital admissions, which serve as stark indicators of clinical instability. The standard of care for managing these events typically includes systemic corticosteroids to quell inflammation. However, this creates a clinical dilemma. While effective acutely, the cumulative exposure to systemic corticosteroids is a major concern, carrying a well-documented risk of significant adverse effects, including osteoporosis, hyperglycemia, and increased susceptibility to infection. Consequently, therapeutic strategies that can decrease the frequency of severe exacerbations, and thereby reduce the reliance on systemic corticosteroids, are of high clinical importance for the long-term management of COPD.

Study Design and Patient Population

To assess the efficacy of dupilumab in a specific COPD cohort, investigators conducted a pooled analysis of two phase 3, randomized, double-blind, placebo-controlled trials, BOREAS and NOTUS. The primary objective was to evaluate the drug's effect on emergency department visits, hospital admissions, and systemic corticosteroid use. The trials enrolled 1,874 patients between the ages of 40 and 85 years with moderate-to-severe COPD. A critical inclusion criterion was evidence of type 2 inflammation, defined as a screening blood eosinophil count of ≥ 300 cells/µL, which identifies the patient population most likely to respond to this targeted therapy. Participants were randomized to receive either dupilumab 300 mg (N = 938) or a matching placebo (N = 936) subcutaneously every two weeks for 52 weeks. The key endpoints measured were the annualized rate of and time to a first emergency department visit or hospital admission, alongside total systemic corticosteroid use.

Reduced Healthcare Utilization with Dupilumab

The analysis of the BOREAS and NOTUS trials revealed a clinically meaningful reduction in the need for acute medical care among patients treated with dupilumab. Over the 52-week study period, dupilumab treatment resulted in a 38% relative reduction in the annualized rate of emergency department visits or hospital admissions for any duration compared to placebo (relative risk: 0.62; 95% confidence interval: 0.43-0.90; P = .0121). This finding points to a substantial decrease in episodes of severe clinical instability requiring urgent intervention. Furthermore, the therapy also extended the time until a patient's first severe event. The data showed that dupilumab reduced the risk of a first emergency department visit or hospital admission by 45% (hazard ratio: 0.55; 95% confidence interval: 0.38-0.78; P = .0010). Together, these results suggest that targeting type 2 inflammation with dupilumab can stabilize patients and lessen the burden on acute healthcare services.

Lower Systemic Corticosteroid Needs

In addition to decreasing hospitalizations, dupilumab treatment also addressed the significant clinical problem of corticosteroid burden. The analysis showed that patients receiving dupilumab required fewer systemic corticosteroids to manage exacerbations. For severe exacerbations, which are the most clinically consequential, patients in the dupilumab group had a 42% lower use of systemic corticosteroids compared to those on placebo (relative risk: 0.58; 95% confidence interval: 0.38-0.89; P = .0126). This effect was also observed in less severe events. For moderate exacerbations, dupilumab treatment was associated with a 28% reduction in systemic corticosteroid use (relative risk: 0.72; 95% confidence interval: 0.60-0.87; P = .0005). These findings are directly relevant to clinical practice, as a reduction in cumulative steroid exposure may help mitigate the long-term risks associated with these medications.

Clinical Implications for COPD Management

For clinicians managing patients with COPD and evidence of type 2 inflammation (eosinophils ≥ 300 cells/µL), this pooled analysis provides important data on the potential benefits of dupilumab. The findings demonstrate a dual impact: a reduction in severe acute events and a concurrent decrease in the need for a cornerstone of exacerbation treatment. The 38% reduction in emergency department visits or hospitalizations (P = .0121) translates directly into fewer crises for patients and a lower strain on the healthcare system. Delaying and reducing the risk of a first such event by 45% (P = .0010) further underscores the therapy's potential to maintain patient stability over the long term. From a practical standpoint, this suggests a more predictable disease course for this high-risk population. Equally important is the demonstrated steroid-sparing effect. By reducing systemic corticosteroid use by 42% for severe exacerbations (P = .0126) and 28% for moderate ones (P = .0005), this therapy offers a strategy to minimize the cumulative toxicity associated with corticosteroids, a persistent challenge in COPD care. These results position dupilumab as a targeted option that can address both acute exacerbation frequency and the iatrogenic burden of treatment in this specific patient phenotype.

References

1. Mohamed MMG, Kamel G, Charbek E. Role of Monoclonal Antibodies in the Management of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-analysis of Randomized Controlled Trials.. Annals of the American Thoracic Society. 2025. doi:10.1513/AnnalsATS.202406-597OC

2. Shamim H, Singh AK, Sharma R, Mishra RK. COPD 2.0: Bronchodilators, biologics and beyond - A systematic review.. Lung India : official organ of Indian Chest Society. 2026. doi:10.4103/lungindia.lungindia_199_25

3. Ziojła-Lisowska K, Kuzio A, Cieplińska A. Treatment of COPD with a particular focus on biological therapy: a systematic review. Quality in Sport. 2024. doi:10.12775/qs.2024.17.53022

4. Christenson SA, Hanania NA, Bhatt SP, et al. Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 2025. doi:10.1016/s2213-2600(25)00044-x

5. Bhatt S, Rabe KF, Hanania NA, et al. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials.. The Lancet Respiratory Medicine. 2025. doi:10.1016/s2213-2600(24)00409-0

6. Pitre T, Lupas D, Mah J, et al. Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.. COPD. 2025. doi:10.1080/15412555.2025.2449889

7. Hu K, Chuang M, Lai C, Liao K. Meta-Analysis of Randomized, Controlled Trials Assessing the Effectiveness and Safety of Biological Treatments in Chronic Obstructive Pulmonary Disease Patients.. Clinical therapeutics. 2025. doi:10.1016/j.clinthera.2024.12.001

8. Alyami HS, Dulaijan AAA, Alhaji AA, et al. THE EFFICACY OF BIOLOGICAL TREATMENT METHODS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS; SYSTEMATIC REVIEW. 2025. doi:10.53555/vaf1rr98

9. Freund O, Wand O, Kutzkel S, et al. Real-World and Patient-Reported Outcomes of Dupilumab and Other Biological Drugs for Chronic Obstructive Pulmonary Disease-A Systematic Review.. Diagnostics (Basel, Switzerland). 2024. doi:10.3390/diagnostics14212390